Adaptive immune response during hepatitis C virus infection
Hepatitis C virus(HCV)infection affects about 170 million people worldwide and it is a major cause of liver cirrhosis and hepatocellular carcinoma.HCV is a hepatotropic non-cytopathic virus able to persist in a great percentage of infected hosts due to its ability to escape from the immune control.L...
Saved in:
Published in: | World journal of gastroenterology : WJG Vol. 20; no. 13; pp. 3418 - 3430 |
---|---|
Main Author: | |
Format: | Journal Article |
Language: | English |
Published: |
United States
Baishideng Publishing Group Co., Limited
07-04-2014
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Hepatitis C virus(HCV)infection affects about 170 million people worldwide and it is a major cause of liver cirrhosis and hepatocellular carcinoma.HCV is a hepatotropic non-cytopathic virus able to persist in a great percentage of infected hosts due to its ability to escape from the immune control.Liver damage and disease progression during HCV infection are driven by both viral and host factors.Specifically,adaptive immune response carries out an essential task in controllingnon-cytopathic viruses because of its ability to recognize infected cells and to destroy them by cytopathic mechanisms and to eliminate the virus by non-cytolytic machinery.HCV is able to impair this response by several means such as developing escape mutations in neutralizing antibodies and in T cell receptor viral epitope recognition sites and inducing HCV-specific cytotoxic T cell anergy and deletion.To impair HCV-specific T cell reactivity,HCV affects effector T cell regulation by modulating T helper and Treg response and by impairing the balance between positive and negative co-stimulatory molecules and between pro-and antiapoptotic proteins.In this review,the role of adaptive immune response in controlling HCV infection and the HCV mechanisms to evade this response are reviewed. |
---|---|
Bibliography: | Juan Ramón Larrubia;Elia Moreno-Cubero;Megha Uttam Lokhande;Silvia García-Garzón;Alicia Lázaro;Joaquín Miquel;Cristian Perna;Eduardo Sanz-de-Villalobos;Translational Hepatology Unit,Guadalajara University Hospital,University of Alcalá,E-19002 Guadalajara,Spain;Department of Medicine and Medical Specialities,School of Medicine,University of Alcalá,E-28801 Alcalá de Henares,Spain Telephone: +34-949-909200 Fax: +34-949-209256 Correspondence to: Juan Ramón Larrubia, MD, MSc, PhD, Translational Hepatology Unit, Guadalajara University Hospital, University of Alcalá, Donante de Sangre st, E-19002 Guadalajara, Spain. juan.larrubia@uah.es Author contributions: Larrubia JR contributed towards the conception and design of the review; Larrubia JR, Moreno-Cubero E and Lokhande MU co-wrote and Larrubia JR revised the manuscript; García-Garzón S, Lázaro A, Miquel J, Perna C and Sanz-de-Villalobos E contributed equally to the supportive work and supervision. |
ISSN: | 1007-9327 2219-2840 |
DOI: | 10.3748/wjg.v20.i13.3418 |